<DOC>
	<DOCNO>NCT02201459</DOCNO>
	<brief_summary>This phase III trial comparing , newly diagnose chronic phase CML patient , nilotinib 600 mg BID standard arm nilotinib 600 mg BID combine interferon alfa 2 ( pegylated form improve tolerance maybe enhance efficacy ) increase dos total 24 month combination , 1:1 randomized manner . The assessment primary efficacy endpoint perform 12 month ( since nilotinib initiation ) rate patient obtain MR4.5 measure time point .</brief_summary>
	<brief_title>Nilotinib ± Peg-IFN First Line Chronic Phase CML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient CPCML , positive Philadelphia chromosome positive BCRABL ( Mbcr transcript ) , diagnose less 3 month prior study entry Age least 18 yearsold less 65 year Patient treatment Nilotinib expect No CML treatment except hydroxyurea and/or anagrelide No previous TKI treatment . No previous treatment IFN even purpose . SGOT SGPT &lt; 2.5 UNL Serum creatinine &lt; 2 UNL No plan allogeneic stem cell transplantation Signed informed consent ECOG score 0 2 Contraindication IFN Transcripts MBcr Pregnancy , lactation HIV positivity , chronic hepatitis B C. Prior concurrent malignancy CML ( exception mention ) History arterial occlusive disease ( peripheral , carotids severe coronary heart disease ) . Permanent elevation total cholesterol triglyceride despite treatment Severe psychiatric/neurological disease ( previous ongoing ) Concomitant autoimmune disease Other investigational product ongoing Ongoing immunosuppressive treatment Ongoing treatment risk induce torsades de pointes QTcF &gt; 450ms despite correction predispose factor ( i.e electrolytes… ) Congenital long QTcF Unstabilised thyroid disorder No health insurance coverage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Peg-IFN , nilotinib , MR4.5 , CML , chronic phase , first-line</keyword>
</DOC>